Glioblastoma Multiforme of Brain Clinical Trial
Official title:
A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma
This is a phase III, non-blinded, blocked randomized clinical trial. The study is conducted on 62 newly diagnosed patients with brain glioblastoma multiforme and anaplastic astrocytoma referring to the oncology clinics during March 2018 and March 2019. The patients will be randomized to 6-cycle and 12-cycle adjuvant Temozolomide groups using block randomization method (1:1).
This study aimed to compare the overall survival and progression free survival between 6 cycles and 12 cycles adjuvant Temozolomide regimens in patients with brain glioblastoma and anaplastic astrocytoma. The main inclusion criterion includes patients newly diagnosed with glioblastoma and anaplastic astrocytoma whose diagnosis is confirmed by histologic evaluation. The main exclusion criteria involve chronic renal, hepatic or cardiac failure. The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage). This is a phase III, non-blinded, blocked randomized clinical trial. The study is conducted on 62 newly diagnosed patients with brain glioblastoma multiforme and anaplastic astrocytoma referring to the oncology clinics during March 2018 and March 2019. The patients will be randomized to 6-cycle and 12-cycle adjuvant Temozolomide groups using block randomization method (1:1). This study will be conducted in the oncology clinic of Omid Hospital and Imam Reza Hospital, Mashhad. Blinding is not observed in this study. The primary endpoints of study are overall survival and progression free survival. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03657576 -
Trial of C134 in Patients With Recurrent GBM
|
Phase 1 | |
Recruiting |
NCT05685004 -
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
Active, not recruiting |
NCT03665545 -
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT02474966 -
Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study
|
Phase 2 | |
Active, not recruiting |
NCT02137759 -
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
|
Phase 2 | |
Enrolling by invitation |
NCT03170141 -
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
|
Phase 1 | |
Recruiting |
NCT04842513 -
Multi Peptide Vaccination With XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma
|
Phase 1 | |
Recruiting |
NCT04869449 -
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
|
Early Phase 1 | |
Not yet recruiting |
NCT05095441 -
A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma
|
Phase 1 | |
Completed |
NCT00003456 -
Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT03047473 -
Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 2 | |
Enrolling by invitation |
NCT05116137 -
The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors
|
N/A | |
Recruiting |
NCT05627323 -
CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma
|
Phase 1 | |
Active, not recruiting |
NCT04968366 -
Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
|
Phase 1 | |
Suspended |
NCT04222309 -
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
|
Phase 1 | |
Not yet recruiting |
NCT06186440 -
Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06273176 -
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
|
||
Recruiting |
NCT06146725 -
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
|
||
Recruiting |
NCT06283927 -
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
|